局灶性癲癇服用吡侖帕奈致皮疹病例報道并文獻學習_Journal of Epilepsy

Authors：

王碧 , 張歆博 ,  劉永紅

1. ;

Corresponding?author：

劉永紅, Email: liuyhong@fmmu.edu.cn

Keywords：

吡侖帕奈; 藥物不良反應; 皮疹

DOI：

10.7507/2096-0247.202401004

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 王碧, 張歆博, 劉永紅. 局灶性癲癇服用吡侖帕奈致皮疹病例報道并文獻學習. Journal of Epilepsy, 2024, 10(2): 155-157. doi: 10.7507/2096-0247.202401004 Copy

1.	Johannessen L, Johannessen S, Patsalos P. Therapeutic drug monitoring of antiepileptic drugs: current status and future prospects. Expert Opin Drug Metab Toxicol, 2020, 16(3): 227-238.
2.	Singh K, Verma N. Teratogenic potential of third-generation antiepileptic drugs: current status and research needs. Pharmacol Rep, 2019, 71(3): 491-502.
3.	Nishida T, Lee S, Wu T, et al. Efficacy and safety of perampanel in generalized and focal to bilateral tonic-clonic seizures: a comparative study of Asian and non-Asian populations. Epilepsy, 2019, 60(Suppl1): 47-59.
4.	Ettinger A, Lopresti A, Yang H, et al. Psychiatric and behavioral adverse events in randomized clinical studies of the non-competitive AMPA receptor antagonist perampanel. Epilepsy, 2015, 56(8): 1252-1263.
5.	張捷, 謝涵, 鄧泂, 等. 基于隨訪6個月療效結局的加用吡侖帕奈治療兒童藥物難治性癲癇的單中心前瞻性隊列研究. 中國循證兒科雜志, 2021, 16(4): 269-274.
6.	Yelshanskaya M, Singh A, Sampson J, et al. Structural bases of ampa-subtype iono-tropic glutamate receptors by antiepileptic drugs. Neuron, 2016, 91(6): 1305-1315.
7.	孟林雪. 吡侖帕奈的抗癲癇作用機制及臨床應用. 癲癇與神經電生理學雜志, 2021(6): 321-326.
8.	Pina-Garza JE, Rosenfeld W, Saeki K, et al. Efficacy and safety of adjunctive parampanelin adolescent patients with epilepsy: post hoc analysis of six randomized studies. Epilepsy Behav, 2020, 104 (Pt A): 106876.
9.	Rektor I, Krauss G, Inoue Y, et al. Assessment of the long term efficacy and safety of adjunctive peampanel in tonic-clonicseizures: analysis of four open label extension studies. Epilepsy, 2020, 61(7): 1491-1502.
10.	Knowles S, Shapirole, Shear N. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drllg Saf, 1999, 21(6): 489-501.
11.	Sehlienger R, Shear N. Antiepileptic drug hypersensitivity syndrome Epilepsy, 1998, 39(Suppl 7): S3-S7.
12.	WHO—UMC. The use of the WHO-UMC system for standardised case causality assessment. [EB/OL]. 2009-07-03[2009-3-0l.
13.	Wood M, Gillard M. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptievesiele 2A protein Epilepsy, 2017, 58(2): 255-262.
14.	陳嬌, 劉曉鳴, 岳璇. 左乙拉西坦添加治療對難治性癲癇患兒外周血多藥耐藥相關蛋白1、2表達的影響. 中華實用兒科臨床雜志, 2017, 32(22): 1737-1740.
15.	Arif H, Uchsbaum R, Weintraub D, et al. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology, 2007, 68(20): 1701-1709.
16.	張夏婷, 劉剛, 孫偉. 左乙拉西坦致皮疹2例. 藥物不良反應雜志, 2011, 13(6): 391-392.
17.	Svendsen T, Brodtkorb E, Baftiu A, et al. Clinical experience combined with therapeutic drug monitoring of lacosamide. Acta Neurologica Scandinavica, 2020, 141(4): 279-286.
18.	Cawello W, Stockis A, Andreas J, et al. Advances in epilepsy treatment: lacosamide pharmacokinetic pofile. Ann N Y Acad sci, 2014, 1329: 18-32.
19.	Cawello W. Clinical pharmacokinetic and pharmacodynamic profile of lacosamide. Clin Pharmacokinct, 2015, 54(9): 90l-914.
20.	Biton V, Nagel A, Isojarvi J, et al. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: analysis of data pooled from three randomized, double blind, placebo-controlled clinical trials. Epilepsy Behav, 2015, 52(2): 119-127.
21.	劉平, 吳茵, 何偉亮, 等. 吡侖帕奈抗癲癇的藥理作用和臨床評. 中國新藥與臨床雜志, 2022, 41(3): 138-142.
22.	Deliso P, Moavero R, Coppola G, et al. Current role of perampanel in Pediatric epilepsy. Ital J Pediatric, 2017, 43(1): 51.

1. Johannessen L, Johannessen S, Patsalos P. Therapeutic drug monitoring of antiepileptic drugs: current status and future prospects. Expert Opin Drug Metab Toxicol, 2020, 16(3): 227-238.
2. Singh K, Verma N. Teratogenic potential of third-generation antiepileptic drugs: current status and research needs. Pharmacol Rep, 2019, 71(3): 491-502.
3. Nishida T, Lee S, Wu T, et al. Efficacy and safety of perampanel in generalized and focal to bilateral tonic-clonic seizures: a comparative study of Asian and non-Asian populations. Epilepsy, 2019, 60(Suppl1): 47-59.
4. Ettinger A, Lopresti A, Yang H, et al. Psychiatric and behavioral adverse events in randomized clinical studies of the non-competitive AMPA receptor antagonist perampanel. Epilepsy, 2015, 56(8): 1252-1263.
5. 張捷, 謝涵, 鄧泂, 等. 基于隨訪6個月療效結局的加用吡侖帕奈治療兒童藥物難治性癲癇的單中心前瞻性隊列研究. 中國循證兒科雜志, 2021, 16(4): 269-274.
6. Yelshanskaya M, Singh A, Sampson J, et al. Structural bases of ampa-subtype iono-tropic glutamate receptors by antiepileptic drugs. Neuron, 2016, 91(6): 1305-1315.
7. 孟林雪. 吡侖帕奈的抗癲癇作用機制及臨床應用. 癲癇與神經電生理學雜志, 2021(6): 321-326.
8. Pina-Garza JE, Rosenfeld W, Saeki K, et al. Efficacy and safety of adjunctive parampanelin adolescent patients with epilepsy: post hoc analysis of six randomized studies. Epilepsy Behav, 2020, 104 (Pt A): 106876.
9. Rektor I, Krauss G, Inoue Y, et al. Assessment of the long term efficacy and safety of adjunctive peampanel in tonic-clonicseizures: analysis of four open label extension studies. Epilepsy, 2020, 61(7): 1491-1502.
10. Knowles S, Shapirole, Shear N. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drllg Saf, 1999, 21(6): 489-501.
11. Sehlienger R, Shear N. Antiepileptic drug hypersensitivity syndrome Epilepsy, 1998, 39(Suppl 7): S3-S7.
12. WHO—UMC. The use of the WHO-UMC system for standardised case causality assessment. [EB/OL]. 2009-07-03[2009-3-0l.
13. Wood M, Gillard M. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptievesiele 2A protein Epilepsy, 2017, 58(2): 255-262.
14. 陳嬌, 劉曉鳴, 岳璇. 左乙拉西坦添加治療對難治性癲癇患兒外周血多藥耐藥相關蛋白1、2表達的影響. 中華實用兒科臨床雜志, 2017, 32(22): 1737-1740.
15. Arif H, Uchsbaum R, Weintraub D, et al. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology, 2007, 68(20): 1701-1709.
16. 張夏婷, 劉剛, 孫偉. 左乙拉西坦致皮疹2例. 藥物不良反應雜志, 2011, 13(6): 391-392.
17. Svendsen T, Brodtkorb E, Baftiu A, et al. Clinical experience combined with therapeutic drug monitoring of lacosamide. Acta Neurologica Scandinavica, 2020, 141(4): 279-286.
18. Cawello W, Stockis A, Andreas J, et al. Advances in epilepsy treatment: lacosamide pharmacokinetic pofile. Ann N Y Acad sci, 2014, 1329: 18-32.
19. Cawello W. Clinical pharmacokinetic and pharmacodynamic profile of lacosamide. Clin Pharmacokinct, 2015, 54(9): 90l-914.
20. Biton V, Nagel A, Isojarvi J, et al. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: analysis of data pooled from three randomized, double blind, placebo-controlled clinical trials. Epilepsy Behav, 2015, 52(2): 119-127.
21. 劉平, 吳茵, 何偉亮, 等. 吡侖帕奈抗癲癇的藥理作用和臨床評. 中國新藥與臨床雜志, 2022, 41(3): 138-142.
22. Deliso P, Moavero R, Coppola G, et al. Current role of perampanel in Pediatric epilepsy. Ital J Pediatric, 2017, 43(1): 51.

Journal of Epilepsy

局灶性癲癇服用吡侖帕奈致皮疹病例報道并文獻學習

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content